166 related articles for article (PubMed ID: 37272766)
21. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells.
Pan H; Jia R; Zhang L; Xu S; Wu Q; Song X; Zhang H; Ge S; Xu XL; Fan X
Int J Biochem Cell Biol; 2015 Mar; 60():176-84. PubMed ID: 25582751
[TBL] [Abstract][Full Text] [Related]
22. BAP1 mutations inhibit the NF-κB signaling pathway to induce an immunosuppressive microenvironment in uveal melanoma.
Zhang C; Wu S
Mol Med; 2023 Sep; 29(1):126. PubMed ID: 37710185
[TBL] [Abstract][Full Text] [Related]
23. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
24. Prognostic parameters in uveal melanoma and their association with BAP1 expression.
van Essen TH; van Pelt SI; Versluis M; Bronkhorst IH; van Duinen SG; Marinkovic M; Kroes WG; Ruivenkamp CA; Shukla S; de Klein A; Kiliç E; Harbour JW; Luyten GP; van der Velden PA; Verdijk RM; Jager MJ
Br J Ophthalmol; 2014 Dec; 98(12):1738-43. PubMed ID: 25147369
[TBL] [Abstract][Full Text] [Related]
25. Population-based analysis of BAP1 germline variations in patients with uveal melanoma.
Repo P; Järvinen RS; Jäntti JE; Markkinen S; Täll M; Raivio V; Turunen JA; Kivelä TT
Hum Mol Genet; 2019 Jul; 28(14):2415-2426. PubMed ID: 31058963
[TBL] [Abstract][Full Text] [Related]
26. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
[TBL] [Abstract][Full Text] [Related]
27. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
28. Piloting a Deep Learning Model for Predicting Nuclear BAP1 Immunohistochemical Expression of Uveal Melanoma from Hematoxylin-and-Eosin Sections.
Zhang H; Kalirai H; Acha-Sagredo A; Yang X; Zheng Y; Coupland SE
Transl Vis Sci Technol; 2020 Sep; 9(2):50. PubMed ID: 32953248
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors.
Huis In 't Veld RV; Ma S; Kines RC; Savinainen A; Rich C; Ossendorp F; Jager MJ
Cancer Immunol Immunother; 2023 Jul; 72(7):2405-2422. PubMed ID: 36997666
[TBL] [Abstract][Full Text] [Related]
30. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
31. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.
Yavuzyigitoglu S; Koopmans AE; Verdijk RM; Vaarwater J; Eussen B; van Bodegom A; Paridaens D; Kiliç E; de Klein A;
Ophthalmology; 2016 May; 123(5):1118-28. PubMed ID: 26923342
[TBL] [Abstract][Full Text] [Related]
32. Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model.
Ma S; Huis In't Veld RV; Hao Y; Gu Z; Rich C; Gelmi MC; Mulder AA; van Veelen PA; Vu TKH; van Hall T; Ossendorp FA; Jager MJ
Invest Ophthalmol Vis Sci; 2024 Jan; 65(1):42. PubMed ID: 38271187
[TBL] [Abstract][Full Text] [Related]
33. Oncologist-led germline genetic testing for uveal melanoma.
Gillies B; Krema H; Chao A; Lando L; Farncombe KM; Butler M; Altomare F; Kim RH
Ophthalmic Genet; 2023 Jun; 44(3):253-261. PubMed ID: 36974392
[TBL] [Abstract][Full Text] [Related]
34. Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome.
Abbassi YA; Le Guin C; Bornfeld N; Bechrakis NE; Zeschnigk M; Lohmann DR
Fam Cancer; 2023 Apr; 22(2):193-202. PubMed ID: 35920959
[TBL] [Abstract][Full Text] [Related]
35. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
[TBL] [Abstract][Full Text] [Related]
36. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma.
van de Nes JA; Nelles J; Kreis S; Metz CH; Hager T; Lohmann DR; Zeschnigk M
Am J Surg Pathol; 2016 Jun; 40(6):796-805. PubMed ID: 27015033
[TBL] [Abstract][Full Text] [Related]
37. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.
Pilarski R; Cebulla CM; Massengill JB; Rai K; Rich T; Strong L; McGillivray B; Asrat MJ; Davidorf FH; Abdel-Rahman MH
Genes Chromosomes Cancer; 2014 Feb; 53(2):177-82. PubMed ID: 24243779
[TBL] [Abstract][Full Text] [Related]
38. Co-occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence.
Yu L; Zhou D; Zhang G; Ren Z; Luo X; Liu P; Plouffe SW; Meng Z; Moroishi T; Li Y; Zhang Y; Brown JH; Liu S; Guan KL
Mol Oncol; 2022 Feb; 16(3):607-629. PubMed ID: 34706158
[TBL] [Abstract][Full Text] [Related]
39. Chromosomal rearrangements in uveal melanoma: Chromothripsis.
van Poppelen NM; Yavuzyigitoglu S; Smit KN; Vaarwater J; Eussen B; Brands T; Paridaens D; Kiliç E; de Klein A
Genes Chromosomes Cancer; 2018 Sep; 57(9):452-458. PubMed ID: 29726589
[TBL] [Abstract][Full Text] [Related]
40. Punctuated evolution of canonical genomic aberrations in uveal melanoma.
Field MG; Durante MA; Anbunathan H; Cai LZ; Decatur CL; Bowcock AM; Kurtenbach S; Harbour JW
Nat Commun; 2018 Jan; 9(1):116. PubMed ID: 29317634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
